Immediate toxicity during fractionated total body irradiation as conditioning for bone marrow transplantation

Citation
A. Buchali et al., Immediate toxicity during fractionated total body irradiation as conditioning for bone marrow transplantation, RADIOTH ONC, 54(2), 2000, pp. 157-162
Citations number
33
Categorie Soggetti
Radiology ,Nuclear Medicine & Imaging","Onconogenesis & Cancer Research
Journal title
RADIOTHERAPY AND ONCOLOGY
ISSN journal
01678140 → ACNP
Volume
54
Issue
2
Year of publication
2000
Pages
157 - 162
Database
ISI
SICI code
0167-8140(200002)54:2<157:ITDFTB>2.0.ZU;2-H
Abstract
Background: Total body irradiation followed by bone marrow transplantation is well established as a part of the conditioning regimen in high dose ther apy. The immediate tolerance of fractionated total body irradiation (FTBI) was investigated prospectively. Methods: From January 1995 to December 1998 162 patients received a FTBI, 6 x2 Gy on 3 consecutive days, lung dose 10 Gy, for allogeneic (n = 112) or a utologous (n = 50) bone marrow transplantation. High dose chemotherapy (mos tly Cyclophosphamide) was administered after the FTBI. A standardized suppo rtive therapy was administered. The immediate toxicity of FTBI was evaluate d prospectively prior to each radiation fraction using a defined questionna ire. Results: Main symptoms distressing the patient during irradiation period we re gastrointestinal symptoms like nausea and emesis. The prevalence of naus ea per fraction increased to 26.1% after the 4th fraction, with a significa nt higher prevalence in children younger than 10 years at 1st and 2nd fract ions. 42.6 and 22.8%, respectively, of all patients complained of nausea an d episodes of emesis, during FTBI. Mild xerostomia and parotiditis were obs erved in 29.9 and 7.1% of all patients. Further gastrointestinal side effec ts during FTBI were loss of appetite in 16.0%, indisposition in 25.3%, mild oesophagitis in 3.7% and diarrhoea in 3.7% of the patients. During FTBI 41 .4% of the patients developed a temporary skin irritation (mild erythema). Pruritus was registered in 3.7% of the patients. Headache was observed in 1 4.8% and Fatigue syndrome in 49.2% of women and 28.3% of men (P < 0.005). Conclusion: FTBI is a well tolerated therapeutic regimen in high dose thera py. The 162 patients investigated revealed no severe immediate side effects . (C) 2000 Elsevier Science Ireland Ltd. All rights reserved.